Multiple sclerosis fatigue can be successfully managed, according to research studies. Fatigue is a common complaint among multiple sclerosis (MS) patients and, unfortunately, it can negatively impact a person’s life. This is why it is so important to properly manage MS fatigue in order to improve quality of life and overall health.
Dr. Sarah Thomas, Professor Peter Thomas, and colleagues created a group-based fatigue management program for multiple sclerosis patients called FACETS (Fatigue: Applying Cognitive behavioral and Energy effectiveness Techniques to lifeStyle). Patients are provided with tools and strategies in order to properly manage their energy and explore different ways to think about fatigue.
The program is conducted through weekly sessions, facilitated by two health care professionals.
FACETS was evaluated and tested by dividing patients into two groups: those who attended FACETS and those who received routine care. The FACETS group had greater improvements in fatigue severity after a four-month follow-up, compared to the routine care group. Overall, the researchers received positive and overwhelming feedback from those in the FACETS group, not only about their enjoyment, but how they would recommend it to others, too.
Across the United Kingdom, health care professionals are cautiously becoming trained in the FACETS course in order to administer it to their own patients increasing the access and availability of the program.
For now, the FACETS program is only available in the U.K., so if you live on the other side of the pond, you will need other coping mechanisms to combat multiple sclerosis fatigue.
Some tips to beat MS fatigue include:
Shingles may be related to an increased risk of multiple sclerosis (MS). The findings came from Taiwanese investigators who found a higher risk of multiple sclerosis during a 12-month follow-up after shingles, or herpes zoster. Common risk factors for multiple sclerosis are genetics, environmental causes, and viral factors. Continue reading…
Multiple sclerosis patients treated with Tysabri (natalizumab) have a 10 times greater risk of developing a deadly brain virus, according to new findings. The virus – John Cunningham virus (JCV) – is a pathogen that causes a rare and deadly condition known as progressive multifocal leukoencephalopathy (PML). Continue reading…